循环肿瘤细胞 (CTC) 计数和分子分析有望彻底改变实体瘤的管理。在过去的二十年里，他们的理解有了显着的发展，涵盖了各种恶性肿瘤的关键生物学发现和临床研究。虽然对于某些肿瘤类型，例如乳腺癌、前列腺癌和结直肠癌，CTC 已准备好进入临床实践，但对于其他肿瘤类型，还需要进行更多研究。 CTC 作为多功能生物标志物，提供对肿瘤生物学、转移进展和治疗反应的见解。这篇综述总结了 CTC 研究的最新进展，并强调了未来的研究方向。特别关注 CTC 和其他循环生物标志物（特别是循环肿瘤 DNA）的同时评估。多分析物评估有可能释放液体活检的全部临床能力。总之，CTC 代表了精准肿瘤学领域的变革性生物标志物，为将科学发现转化为患者护理的切实改善提供了非凡的机会。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Circulating tumor cells (CTCs) enumeration and molecular profiling hold promise in revolutionizing the management of solid tumors. Their understanding has evolved significantly over the past two decades, encompassing pivotal biological discoveries and clinical studies across various malignancies. While for some tumor types, such as breast, prostate, and colorectal cancer, CTCs are ready to enter clinical practice, for others, additional research is required. CTCs serve as versatile biomarkers, offering insights into tumor biology, metastatic progression, and treatment response. This review summarizes the latest advancements in CTC research and highlights future directions of investigation. Special attention is given to concurrent evaluations of CTCs and other circulating biomarkers, particularly circulating tumor DNA. Multi-analyte assessment holds the potential to unlock the full clinical capabilities of liquid biopsy. In conclusion, CTCs represent a transformative biomarker in precision oncology, offering extraordinary opportunities to translate scientific discoveries into tangible improvements in patient care.Copyright © 2024 Elsevier B.V. All rights reserved.